# OnCo record cellcentric (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/cellcentric/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "cellcentric" ;
  schema:name "CellCentric"@en ;
  schema:alternateName "CellCentric Ltd."@en, "CellCentric Limited"@en, "Cellcentric"@en ;
  schema:description "A Cambridge, UK, company developing inobrodib, a capsule that blocks two proteins (p300 and CBP) that switch on cancer-driving genes. It is being tested mainly in multiple myeloma that has come back or stopped responding, including in late-stage trials."@en ;
  schema:url <https://onco.cc/companies/cellcentric/>, <https://www.cellcentric.com/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://www.cellcentric.com/>, <https://www.cellcentric.com/clinical-trials/>, <https://www.cellcentric.com/our-story/>, <https://www.cellcentric.com/press-release/cellcentric-announces-oversubscribed-220-million-series-d-financing-to-advance-pivotal-trials-of-inobrodib-in-multiple-myeloma/>, <https://find-and-update.company-information.service.gov.uk/company/04948632>, <https://www.racap.com/portfolio/cellcentric> ;
  schema:addressCountry "GB" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  onco:sections <https://onco.cc/fronts/epigenetics/>, <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/epigenetic-drugs/> ;
  onco:targets <https://onco.cc/targets/ep300/>, <https://onco.cc/targets/crebbp/> ;
  onco:drugs <https://onco.cc/drugs/inobrodib/> ;
  onco:trials <https://onco.cc/trials/nct04068597/> .